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The normal epithelial cell-specific 1 (NES1) gene (also known as
KLK10, based on the official nomenclature) resides on chromo-
some 19q13.3–4, spans about 5.5 kb of genomic DNA sequence
and contains 6 exons and 5 introns. NES1 encodes for a secreted
serine protease, whose amino acid sequence has 35–40% identity
and 50–55% similarity with other members of the human
kallikrein family (including human kallikrein 1, human kallikrein
2, and prostate specific antigen) (Liu et al, 1996; Luo et al, 1998).
Thus, the NES1 gene is considered to be a new member of this
family (Diamandis et al, 2000). The physiological function of
NES1 is still not clear. The NES1 gene was identified by virtue of
its down-regulation in breast cancer cell lines, and it is considered
to be involved in the regulation of normal cell growth. Further
experimental evidence suggests that NES1 may function as a
tumour suppressor gene. When the NES1 gene was transfected
into the tumorigenic breast cancer cell line MDA-MB-231, its
anchorage-independent growth was reduced and when this cell
line was inoculated into nude mice, tumour formation was signifi-
cantly decreased (Goyal et al, 1998). 
NES1 is highly expressed in testicular tissue (Liu et al, 1996).
Based on the observations in breast cancer, we hypothesized that
the expression of this gene might also be altered in testicular
tumours. Testicular cancer is the most common malignancy of
young males. In North America, its annual incidence rate is
3–4/100 000 (Coleman et al, 1993). About 90% of the testicular
tumours originate from germ-cell tissues (germ-cell tumours,
GCTs) and only 10% are derived from interstitial tissues (non-
germ-cell tumours), such as the rare Leydig cell tumour.
According to the World Health Organization, testicular GCTs are
classified into seminomas and nonseminomas. Nonseminomas are
further divided into various subgroups based on their histologic
types, including embryonal carcinoma, teratoma, choriocarci-
noma, and other tumours made up of more than one histologic
type. GCTs are malignant tumours, except for mature teratoma
which often has a more benign clinical course (Einhorn, 1994).
GCTs originate from a common pre-invasive lesion, carcinoma in
situ, CIS (Skakkebaek, 1972; Skakkebaek et al, 1987). The events
involved in initiation and progression from normal germ cells to
CIS, then to malignant GCTs are still unknown. It is believed that
aberrant gonadal development may be responsible for the origin
of CIS (Skakkebaek et al, 1987; Rajpert-De Meyts et al, 1998),
whereas both oncogenes and tumour suppressor genes contribute
to the invasive transformation to overt tumours (Dean and Moul,
1998; Looijenga and Oosterhuis, 1999). 
In this study, we investigated the expression of NES1 in normal
and malignant testicular tissues at the RNA and protein level, and
found differential expression of this gene during progression of
germ cell neoplasia. 
MATERIALS AND METHODS 
Testicular specimens 
14 matched samples of tumours and adjacent morphologically
normal testicular tissues were obtained from patients who had
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undergone radical orchiectomy at the University Hospital Charite,
Berlin, Germany. Patient age ranged from 23–60 years with a
median of 36. All patients had a histologically confirmed diag-
nosis of primary testicular germ cell cancer and received no treat-
ment before surgery. The samples included 6 seminomas and 8
non-seminomas (teratomas, embryonal carcinomas and choriocar-
cinomas). 6 randomly selected seminomas (without matched
normal tissues) were also included. 8 normal testicular tissue spec-
imens were obtained from patients who had orchiectomy for
prostate cancer. Subsequently, 6 additional testicular tumour spec-
imens that included CIS and Leydig tumour, and 2 human embry-
onal carcinoma cell lines, NTERA-2 and 2102Ep were obtained
from the National University Hospital, Copenhagen, Denmark. 
Total RNA extraction 
Tissue specimens were minced with a scalpel, on ice, and immedi-
ately transferred into a 2 ml polypropylene tube. They were then
homogenized and total RNA was extracted using RNeasy mini
spin columns (QIAGEN Inc., Valencia, CA) following the manu-
facturer’s instructions. Total RNA concentration and its purity
were determined spectrophotometrically. 
Reverse transcriptase-polymerase chain reaction 
(RT-PCR) 
2 mg of total RNA were converted to cDNA with the Superscript™
Preamplification Kit (Gibco BRL, Gaithersburg, MD), following
the manufacturer’s recommendations. The final volume was 20 ml.
2 PCR primers were designed to amplify the NES1 cDNA. Their
sequences are as follows: forward, 5¢-GATCACCTGCT-
GCTTCTTC-3¢; reverse, 5¢-CACTCTGGCAAGGGTCCTG-3¢.
The expected size of the PCR product is 383 bp. The actin primers
are: forward, 5¢-ACAATGAGCTGCGTGTGGCT-3¢; reverse,
TCTCCTTAATGTCACGCACGA-3¢. The amplified PCR product
is 372 bp. PCR was carried out in a 20 ml reaction mixture,
containing 1 ml of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl2, 200 mM dNTPs (deoxynucleoside triphosphates),
100 ng primers and 2.5 units of HotstarTaq™ DNA polymerase
(QIAGEN) on a Perkin-Elmer 9600 thermal cycler. In all PCR
reactions, a blank control (water was used as the template) was
always included. The same PCR conditions were used for both
NES1 gene and actin gene amplification. They were 94°C for 15
minutes to activate the polymerase, followed by 30 cycles of dena-
turing at 94°C for 30 seconds, annealing at 62°C for 30 seconds,
and extension at 72°C for 30 seconds. The final extension was at
72°C for 5 minutes. Equal amounts of PCR products were then
separated on a 2.5% agarose gel, stained with ethidium bromide,
and visualized under UV light. 
Immunohistochemical localization of NES1 protein 
A rabbit polyclonal antibody was raised against the NES1 gene
full-size recombinant protein produced in yeast cells.
Immunohistochemical staining for NES1 was performed
according to a standard indirect immunoperoxidase method.
Briefly, frozen or fixed and paraffin-embedded tissue sections
were thawed or fixed and dewaxed. The procedure was performed
at room temperature (RT) unless otherwise specified. To block an
unspecific antibody binding, 10% non-immune goat serum was
applied to sections for 20 min. The endogenous activity of peroxi-
dase was not blocked by an incubation with a hydrogen peroxide
solution (which is normally a part of the protocol) because the
specific staining was somewhat weaker after this pretreatment.
However, it is known from numerous previous experiments that
erythrocytes are the only cell type in the testis that exhibits
endogenous peroxidase activity. Subsequently, the sections were
incubated with the primary anti-NES1 antibody overnight at +4°C.
For each specimen, a negative control was incubated with the Tris
buffer instead of the primary antibody. After triple wash in Tris
buffer, a biotinylated goat-anti-rabbit link antibody was applied,
followed by a streptavidin-peroxidase conjugate (both from
Zymed). The red colour at the site of reaction was visualized by
adding a solution of acetyl carbazole (ACE) and hydrogen
peroxide (Zymed). Finally, the sections were lightly counter-
stained with haematoxylin and mounted with cover slips using an
aqueous, glycerol-based mounting medium (DAKO). 
RESULTS 
In order to investigate the potential role of the NES1 gene in testic-
ular tumorigenesis, we examined NES1 gene expression in the
normal human testis, in a panel of testicular tumours and in 2
germ-cell-tumour derived cell lines. We examined the expression
at the RNA level by RT-PCR and at the protein level by immuno-
histochemistry. To ensure that equal amounts of cDNA were used
for RT-PCR in different samples, the actin gene was also amplified
as a control. We first compared NES1 gene expression in 14 paired
tumour/normal testicular tissues. As shown in Figure 1, for all 14
pairs, the expression of NES1 was abundant in normal testicular
tissues, but was markedly lower or undetectable in the tumour
samples. The actin gene (control) has similar expression level in
tumours and adjacent tissues, indicating that the reduced NES1
expression in cancerous tissues is not due to the amount of RNA
used. We further examined NES1 expression in 6 randomly
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Figure 1 NES1 gene expression in paired cancerous/normal tissues as
assessed by RT-PCR. The normal tissues were obtained from the adjacent
non-cancerous parts in the same testis. The upper and lower panels show
the PCR products of the NES1 gene and actin gene, respectively. Lane M:
molecular weight marker. Odd lanes: normal tissues. Even lanes: cancerous
tissues (lanes 2, 4, 6, 10, 12, 14, 22, 28: non-seminomas; lanes 8, 16, 18, 20,
24, 26: seminomas) 222 L-Y Luo et al 
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selected specimens of seminoma and 8 normal testicular tissues
from different individuals (unpaired cancerous/normal tissues).
For all 8 normal testicular tissues, the expression of NES1 was
uniformly high. However, for all 6 testicular tumours, NES1 gene
expression was either low or undetectable (Figure 2). These results
further confirmed that the expression of NES1 gene was high in the
normal testis but it was markedly decreased in testicular GCTs. 
Subsequently, we examined the expression of NES1 in testicular
tumours with different histologic types. One specimen with a
widespread CIS (80–90% of CIS tubules, as established by a histo-
logical examination of adjacent tissue sections), and a Leydig cell
tumour demonstrated nearly as high level of NES1 expression
as normal parenchyma, whereas seminoma, nonseminoma, and
embryonal carcinoma cell lines had very low expression (Figure
3). This indicated that the NES1 gene is down-regulated or not
present in overt GCTs, but its expression is high in a non-germ cell
testicular tumour (the Leydig cell tumour), and the tissue with CIS,
which retains the architecture of testicular parenchyma. In the
latter case, somatic cells are present, but the majority of normal
germ cells are replaced by the pre-invasive CIS cells. 
The interpretation of these data depended upon the cellular
localization of NES1 protein. To that end, we have raised a poly-
clonal rabbit-anti-human NES1 antibody and performed immuno-
histochemical staining (Figure 4). In paraffin sections, the results
of immunostaining differed somewhat depending upon the fixative
used, however, in all fixatives, the normal testis showed a clear
staining of germ cells, mainly spermatogonia. A diffuse staining
was also observed in Sertoli cells, especially in areas adjacent to
spermatogonia and the basement membrane of seminiferous
tubules. A weak reaction was seen in some Leydig cells, mainly in
sections fixed in Bouin’s fluid. To eliminate the influence of fixa-
tives, the immunostaining was also performed in frozen speci-
mens, and the localization of the NES1 protein to spermatogonia
(strong) and adjacent Sertoli cells (weaker) was confirmed (Figure
4). The sections with CIS which were obtained from the same
orchiectomy specimen used earlier for the RT-PCR experiments,
demonstrated a clear staining of CIS cells. Preliminary results
from staining of a few overt tumours indicated that there may be a
differential expression of the NES1 protein in germ cell tumours;
seminomas appeared to be negative, whereas some highly differ-
entiated elements present within mature teratomas were NES1-
positive. That would explain the presence of detectable NES1
expression in some tumours in the RT-PCR experiments (e.g. line
4 and 28 in Figure 1). 
DISCUSSION 
In this study, we report for the first time that the NES1 gene
is differentially expressed in testicular germ-cell tumours, in
comparison to normal testicular tissues. The mechanism under-
lying this finding is not clear, but this data are in accord with
previous reports, which suggest that NES1 may function as a
tumour suppressor gene (Liu et al, 1996; Goyal et al, 1998). 2
general mechanisms have been proposed for the down-regulation
of tumour suppressor genes in cancer (Lee et al, 1991). First, dete-
riorate mutations in tumour suppressor genes could alter their
expression. In testicular GCTs mutations have been reported
exceedingly rarely. One example may be the tumour suppressor
p16 (a cell cycle regulatory protein), which is found to be down-
regulated in a proportion of testicular tumours. The p16 gene
exhibits high mutations frequency in tumour samples but not
in matching normal controls (Heidenreich et al, 1998). Second,
down-regulation of tumour suppressor genes may be due to
suppression of their regulatory factors (transcriptional modula-
tion). This mechanism is thought to contribute to the down-
regulation of retinoblastoma (RB) gene in testicular cancer
(Strohmeyer et al, 1991). A similar mechanism might also apply to
the NES1 gene for the following reasons: (a) The NES1 gene is
down-regulated in breast cancer cell lines, but no deletions or
rearrangements of the NES1 gene have been detected (Liu et al,
1996), (b) Chromosome 19q 13.3–4, the region where the NES1
gene resides, is not prone to deletions or rearrangements in testic-
ular cancer (Dean and Moul, 1998). However, one has to keep in
mind that the testis and testicular GCTs differ from other tissues
with regard to regulation of proliferation, mainly because of the
unique biology of germ cells, which are capable of undergoing 2
types of cell division: mitotic and meiotic. Moreover, CIS cells and
GCTs retain to a large extent embryonic-like pluripotency and 
may differentiate to a range of diverse somatic and even extra-
embryonic tissues (Andrews, 1998). Thus, the results of investiga-
tions of gene expression in these tumours have to consider the
delicate balance between cellular proliferation and differentiation. 
In general, the expression of NES1 in testicular GCTs was low
or undetectable in overt tumours, both seminomas and non-semi-
nomas, but a couple of tumour samples showed some expression at
the RNA level. In the case of seminomas it may be explained by a
possible presence of tubules with CIS (or even single non-malig-
nant tubules) within the tumour tissue, which is frequently seen.
The relatively highest NES1 expression was though seen in 2 non-
seminomas. This was explained by the immunohistochemical
studies at the protein level which clearly showed that in analogy to
normal somatic epithelial tissues, some highly differentiated
epithelial elements of teratomas and teratocarcinomas displayed a
high level of NES1 expression. In contrast to invasive seminomas,
the pre-invasive precursor of GCTs, carcinoma in situ (CIS),
retained a high expression of NES1, similarly to normal spermato-
gonia. CIS cells have a similar phenotype to overt seminomas, and
very few differences between these 2 cell types have been reported
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Figure 2 NES1 gene expression in unpaired cancerous and normal
testicular tissues as assessed by RT-PCR. The upper and lower panels show
the PCR products of the NES1 gene and actin gene, respectively. Lane 1–6,
cancerous testicular tissues (all seminomas). Lane 7–14, normal testicular
tissues 
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Figure 3 The expression of NES1 gene in normal testicular tissue and
different histologic types of testicular tumour specimens. The upper and
lower panels show the PCR products of the NES1 gene and actin gene,
respectively. Lane 1, carcinoma in situ; 2, normal parenchyma; 3, Leydig cell
tumou; 4, seminoma; 5, non-seminoma; 6, embryonal carcinoma-derived
NTERA-2 cell line (pluripotent); 7, embryonal carcinoma-derived 2102Ep cell
line (nullipotent). 8, Blank control for PCR NES1 gene expression in testis 223
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so far. The most important among them is p18 (INK4c), an
inhibitor of cyclin-dependent kinase, which is abundant in CIS but
down-regulated in seminoma (Bartkova et al, 2000). 
As far as the normal tesis is concerned, our study clearly
demonstrated that the expression of the NES1 gene was mainly
localized in spermatogonia. There may be a low level of expres-
sion in Sertoli cells, or a diffusion of the secreted protein, but the
weak staining observed in our preliminary immunohistochemical
experiments was dependent on the method of tissue preservation,
and may be a result of the cross-reaction with another protein.
Further studies on a larger number of tissue samples will be neces-
sary to draw definitive conclusions. 
NES1 is a new member of the kallikrein gene family. All
kallikrein enzymes described so far are secreted proteins and some
of them are valuable circulating cancer biomarkers (Diamandis et
al, 2000). The most notable example is prostate specific antigen
(PSA) (Stamey et al, 1987; Oesterling, 1991). PSA is a favourable
marker for breast cancer prognosis (Yu et al, 1995). Also, the ratio
between free PSA and human kallikrein 2 has potential for distin-
guishing prostate cancer from benign prostate hyperplasia
(Magklara et al, 1999). Since NES1 is also a secreted protein, we
speculate that it may be detectable in blood or semen samples, and
may have value as a biomarker of testicular function and tumour
progression. 
In summary, in this study, we found that the NES1 gene 
is expressed primarily by normal germ cells and is universally 
under-expressed in testicular germ-cell tumours. The high expres-
sion in some differentiated tumours suggests that transcriptional
regulation rather than structural loss is the mechanism responsible
for the low NES1 expression in germ-cell tumours. We hypothesize
that the NES1 gene expression may be linked to proliferation of
germ cells and may play a role in progression of testicular cancer,
consistent with a putative tumour suppressor function of this protein. 
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